GGrantIndex
Sort

82,697 grants matching vaccine development

Molecular Genetics and Pathogenesis of Anthrax

$770,302
Stephen Leppla · National Institute Of Allergy And Infectious Diseases · ZIA · FY2022 · AI

Vectors and Methods to Increase Immunogenicity during DNA Vaccination

$770,191
Barney Graham · National Institute Of Allergy And Infectious Diseases · ZIA · FY2011 · AI

Duration of Hormonal Contraceptive Use: Immune Responses & Vaginal Microbiota

$770,085
Khalil G Ghanem · Johns Hopkins University · R01 · FY2015 · AI

Administrative Core

$770,083
Jenny P.y. Ting · Univ Of North Carolina Chapel Hill · U19 · FY2016 · AI

Promoting Adherence to TB Regimens in High-Risk Youth

$770,041
Melbourne F Hovell · San Diego State University · R01 · FY2007 · HL

Protection and Immunity after Polyanhydride Nanoparticle Vaccination against Avian Influenza A Virus

$770,038
Kevin L Legge · University Of Iowa · R01 · FY2023 · AI

**AWARDS ISSUED PRIOR TO JANUARY 20, 2025, WERE FUNDED UNDER PREVIOUS ADMINISTRATIONS AND MAY NOT REFLECT THE PRIORITIES AND POLICIES OF THE CURRENT ADMINISTRATION.** AFRICAN SWINE FEVER VIRUS (ASFV) IS WIDESPREAD IN MANY SWINE PRODUCING COUNTRIES, CAUSING LARGE ECONOMIC LOSSES AND AFFECTING GLOBAL FOOD SECURITY. THERE ARE NO EFFECTIVE VACCINES OR TREATMENTS AVAILABLE FOR ASFV. ALTHOUGH THERE ARE STRONG EVIDENCE SUGGESTING THAT ANTIBODY IS AN IMPORTANT COMPONENT OF THE PROTECTIVE IMMUNITY, THE IDENTITY OF VIRAL PROTEINS CAPABLE OF ELICITING PROTECTIVE ANTIBODY RESPONSES IN PIGS REMAIN ELUSIVE. THIS KNOWLEDGE GAP SEVERELY HINDERS THE DEVELOPMENT OF EFFECTIVE ASFV VACCINES. IT IS OBSERVED THAT PIGS SURVIVING AN INFECTION WITH AN ASFV STRAIN OR THOSE IMMUNIZED WITH A LIVE-ATTENUATED VACCINE STRAIN DEVELOP SOLID HOMOLOGOUS PROTECTIVE IMMUNITY. ON THE OTHER HAND, PIGS VACCINATED WITH EXPERIMENTAL INACTIVATED ASF VACCINES DO NOT. WE HYPOTHESIZE THAT PIGS INFECTED WITH A LIVE ASFV STRAIN DEVELOP A DIFFERENT ANTIBODY PROFILE AS COMPARED TO THOSE VACCINATED WITH AN INACTIVATED VACCINE.THE PRIMARY GOAL OF THIS PROPOSED RESEARCH IS TO IDENTIFY VIRAL PROTEINS CAPABLE OF ELICITING A PROTECTIVE IMMUNE RESPONSE IN PIGS. IN THIS CURRENT APPLICATION, WE PROPOSE TO EMPLOY OUR RECENTLY DEVELOPED HIGH-THROUGHPUT ASSAY TO SYSTEMATICALLY SCREEN THE WHOLE ASFV PROTEOME USING ANTISERA COLLECTED FROM (1) PIGS RECOVERED FROM A NATURAL INFECTION WITH HIGHLY VIRULENT ASFV STRAIN IN THE FIELD, (2) PIGS VACCINATED WITH A LIVE-ATTENUATED ASF VACCINE AND (3) PIGS VACCINATED WITH AN INACTIVATED VACCINE. SUBSEQUENTLY, WE USED STATISTICAL TOOLS TO COMPARATIVELY ANALYZE ANTIBODY PROFILES AMONG THESE THREE POPULATIONS OF PIGS TO IDENTIFY VIRAL PROTEINS THAT HAVE THE POTENTIAL OF ELICITING PROTECTIVE ANTIBODY AGAINST ASFV.

$770,000
Board Of Regents Of The University Of Nebraska · · FY2022 · National Institute of Food and Agriculture

Recurrent Tumor-Specific Alternately Processed Transcripts as a Source of Neoantigens for NF1-associated Malignant Peripheral Nerve Sheath Tumor Immunoprevention

$770,000
David Andrew Largaespada · University Of Minnesota · UH3 · FY2023 · CA

Recurrent Tumor-Specific Alternately Processed Transcripts as a Source of Neoantigens for NF1-associated Malignant Peripheral Nerve Sheath Tumor Immunoprevention

$770,000
David Andrew Largaespada · University Of Minnesota · UH3 · FY2021 · CA

Novel Concepts for the Eradication of HIV

$770,000
Rafick-Pierre Sekaly · Oregon Health & Science University · DP1 · FY2009 · DA

Hunting the HIV-1 Unicorn

$770,000
Sara Sawyer · University Of Colorado · DP1 · FY2019 · DA

Hunting the HIV-1 Unicorn

$770,000
Sara Sawyer · University Of Colorado · DP1 · FY2018 · DA

Integrating genomics and the protein interactome for HPV+ head and neck cancer therapy

$769,993
Jennifer R Grandis · University Of California, San Francisco · R35 · FY2020 · CA

Influence of maternal virome and HIV status on infant gut virome, growth and immunity

$769,959
Heather Beryl Jaspan · Seattle Children'S Hospital · R01 · FY2022 · HD

A Multidisciplinary Approach to Understanding TB Latency and Reactivation

$769,928
Petros C Karakousis · Johns Hopkins University · R01 · FY2012 · HL

Ontogeny and metabolism of lung alveolar macrophages in tuberculosis

$769,925
Lu Huang · Univ Of Arkansas For Med Scis · R01 · FY2024 · AI

Sex specific immune response to SARS-CoV-2 leads to chronic neurologic symptoms

$769,918
Louise Deborah McCullough · University Of Texas Hlth Sci Ctr Houston · R01 · FY2024 · MH

Reactions And Immunochemistry Of Carbohydrates

$769,891
Pavol Kovac · National Institute Of Diabetes And Digestive And Kidney Diseases · ZIA · FY2015 · DK

Vascular macrophages and T cells in atherosclerosis

$769,886
Klaus F. Ley · Augusta University · R35 · FY2025 · HL

Mucosal subunit vaccines against SARS CoV-2

$769,833
Purnima Dubey · Ohio State University · R01 · FY2024 · AI

Mechanisms of Chronic Hepatitis B Infection and Therapeutic Vaccines

$769,814
David R. Milich · Vaccine Research Institute Of San Diego · R01 · FY2009 · AI

Early HIV Effects on Gut Immunity and Inflammation for Seeding Viral Reservoirs

$769,753
Satya Dandekar · University Of California At Davis · R01 · FY2017 · AI

A novel nanochannel system for sustained delivery of Tenofovir Alafenamide Fumarate and Emtricitabine for HIV pre-exposure prophylaxis

$769,740
Alessandro Grattoni · Methodist Hospital Research Institute · R01 · FY2019 · AI

Global Network for Women's and Children's Health

$769,705
Edward A Liechty · Indiana University Indianapolis · U01 · FY2012 · HD

Vascular macrophages and T cells in atherosclerosis

$769,654
Klaus F. Ley · Augusta University · R35 · FY2023 · HL